Pulmonary Arterial Hypertension Market Size And Share

  • Report Code : TIPRE00005221
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 174
Buy Now

Pulmonary Arterial Hypertension Market Size, Share, and Forecast by 2028

Buy Now

Pulmonary Arterial Hypertension Market: Strategic Insights

Pulmonary Arterial Hypertension Market

  • CAGR (2021 - 2028)
    5.8%
  • Market Size 2021
    US$ 7.37 Billion
  • Market Size 2028
    US$ 10.89 Billion

Market Dynamics

GROWTH DRIVERS
  • Rising cases of pulmonary arterial hypertension (PAH)
  • New targeted therapies for PAH treatment
FUTURE TRENDS
  • Shift toward oral therapies for PAH management
  • Development of new drug classes for PAH treatment
OPPORTUNITIES
  • Growth of generics and biosimilars in PAH treatments
  • Research into combination therapies and personalized medicine

Key Players

  • Johnson Johnson
  • Gilead Sciences Inc
  • United Therapeutics Corp
  • Bayer AG
  • Aerami Therapeutics Holdings Inc
  • Novartis AG
  • GSK Plc
  • Teva Pharmaceutical Industries Ltd
  • Lupin Ltd

Regional Overview

  • North America
  • Europe
  • Asia-Pacific
  • South and Central America
  • Middle East and Africa

Market Segmentation

Drugs
  • Endothelin Receptor Antagonists
  • Prostacyclin and Prostacyclin Analogs
  • sGC Stimulators
  • pde-5 Dipsticks
Type
  • Branded and Generics
Route of Administration
  • Oral
  • Intravenous/Subcutaneous
  • Inhalational
Distribution Channel
  • Hospital Pharmacies and Clinics
  • Online Pharmacies
  • Retail Pharmacies